Drug Discovery & Development on Twitter: “An inexpensive investigational #Vaccine is stable for weeks at room temperature & can potentially be used for both prime & boost #Vaccination. Developer Akston #Biosciences, has hooked up with @LakePharma to #Manufacture it https://drugdiscoverytrends.com/akston-biosciences-and-lakepharma-team-up-on-second-generation-covid-19-vaccine/… #ClinicalTrials @researchumcg”
PitchBook: “Eurazeo to sell pharma company Seqens”
Once Competitors, Local TV Stations Are Sharing Resources
RepublicWorld.com (India): “Akston Biosciences Launches Phase I/II Clinical Trial Of Second-Generation COVID-19 Vaccine: Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate”
Hebrew SeniorLife: “Hebrew SeniorLife Named a Top Place to Work for 2021 by The Boston Globe: Nonprofit Senior Care Organization Ranked 24th of the Top Largest Companies”
Hebrew SeniorLife: “Hebrew SeniorLife Raises More than $1.2 Million at 9th Annual EngAGE Proceeds will benefit Hebrew SeniorLife’s health care, communities, research, and teaching that transform the experience of aging”
New York Times Validates Prediction about Local News
Canton Community TV: “In the Spotlight-Alegria Cohen on Malnutrition in Seniors”
M2 Pharma: “Akston Biosciences collaborates with LakePharma to develop commercial quantities of Akston’s COVID-19 vaccine candidate”
Newstral.com: “A Cable Bull Goes Neutral on the Stocks. Here’s Why.”
eHop: “Hopkinton might end up playing a key role in helping to end the COVID-19 pandemic, as the biotech company LakePharma announced that it will work to develop and produce a vaccine at its facility on South Street”
Eagle-Tribune: “COVID-19 vaccine developed by Beverly company reaches trial stage”